Incyte (INCY) Cash & Equivalents Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.69% |
| Dec 31, 2025 | 15.41% |
| Sep 30, 2025 | 10.39% |
| Jun 30, 2025 | 8.06% |
| Mar 31, 2025 | 13.23% |
| Dec 31, 2024 | -1.63% |
| Jun 30, 2024 | -6.96% |
| Mar 31, 2024 | 20.82% |
| Dec 31, 2023 | 22.52% |
| Sep 30, 2023 | 23.75% |
| Jun 30, 2023 | 135.53% |
| Mar 31, 2023 | 122.01% |
| Dec 31, 2022 | 26.83% |
| Sep 30, 2022 | 18.99% |
| Jun 30, 2022 | 40.07% |
| Mar 31, 2022 | 44.21% |
| Dec 31, 2021 | 25.83% |
| Sep 30, 2021 | 28.07% |
| Jun 30, 2021 | 29.81% |
| Mar 31, 2021 | 20.49% |
| Dec 31, 2020 | 23.74% |
| Sep 30, 2020 | 27.43% |
| Jun 30, 2020 | 24.72% |
| Mar 31, 2020 | 19.85% |
| Dec 31, 2019 | 32.29% |
| Jun 30, 2019 | 28.37% |
| Mar 31, 2019 | 24.38% |
| Dec 31, 2018 | 19.81% |
| Sep 30, 2018 | 32.52% |
| Jun 30, 2018 | -30.06% |
| Mar 31, 2018 | -27.76% |
| Dec 31, 2017 | 32.05% |
| Sep 30, 2017 | 36.38% |
| Jun 30, 2017 | 11.89% |
| Mar 31, 2017 | 9.31% |
| Dec 31, 2016 | 19.02% |
| Sep 30, 2016 | 13.18% |
| Jun 30, 2016 | 6.31% |
| Mar 31, 2016 | 11.72% |
| Dec 31, 2015 | 4.53% |
| Sep 30, 2015 | 2.77% |
| Jun 30, 2015 | 1.21% |
| Mar 31, 2015 | 0.83% |